Calcium Fracture Study

Completed

• Conditions: Postmenopausal fractures; Reproductive Health and Childbirth - Menstruation and menopause; Other - Fractures

• Registration Number: ACTRN12605000242628
• Lead Sponsor: Professor I Reid

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-08-31
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 1500

Inclusion Criteria

Females >5 years postmenopausal and aged >55 years with life-expectancy >5 years.

Exclusion Criteria

Renal impairment (serum creatinine > 0.2mmol/l), Untreated hypo- or hyperthyroidism, Active liver disease, Serum 25-hydroxyvitamin D < 14 ng/ml, Concurrent major systemic disease, including malignancy, Metabolic bone disease, Regular use of hormone replacement therapy within the previous 1 year, Regular use of sodium fluoride in a dose greater than or equal to 20mg per day in the previous 1 year, Regular use of anabolic steroid preparations in the previous 1 year, Treatment with bisphosphonates in the previous 1 year, Current treatment with glucocorticoid drugs, Calciferol supplements in doses >1000 iu/day or 50,000 iu/month, Lumbar spine bone density < mean-2.0 SD for age-appropriate data.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time to first clinical fracture[5 years]

Secondary Outcome Measures

Name	Time	Method
Total vertebral fractures.[5 years];Hip fractures.[5 years];Forearm fractures.[5 years];Osteoporotic fractures.[5 years];The difference between fall frequency over 5 years in the calcium-treated group compared to the incidence in the control group.[5 years]